<P>&nbsp;</P> <P align=justify><STRONG>Announced by French President Fran&#231;ois Hollande, the IMODI (Innovative MODels Initiative) project will, after signing of the final contract with OSEO, benefit from &#8364;13.4 million</STRONG> as the winner of the &#8220;Core Competitiveness Cluster Research and Development Projects&#8221; (Projets de Recherche et de D&#233;veloppement Structurants des P&#244;les de Comp&#233;titivit&#233;) call for projects. This funding will be used to set up the <A title="" href="https://www.aderly.com/publications/Oncology,id_635.pdf" target=_blank>first nationwide personalized medicine program in the field of oncology</A>, backed by an overall budget of &#8364;41 million.</P> <P align=justify><BR><STRONG>This seven-year project, led and coordinated by Oncodesign, brings together six industrial groups</STRONG> (Sanofi, Servier, Ipsen, Pierre Fabre, Transg&#232;ne and Biofortis), four SMEs, including Lyonbiop&#244;le members CTI BIOTECH and Oncodesign, and seven academic institutions, including Lyon&#8217;s L&#233;on B&#233;rard Cancer Research Center and Synergie Lyon Cancer, from five accrediting competitiveness clusters. </P> <P align=justify><BR><STRONG>A number of key players from the Lyon area are thus involved, including CTI-BIOTECH</STRONG>, a young Lyon firm specializing in research and innovation in the fields of cell therapy, regenerative medicine, stem cells and tissue engineering for the pharmaceutical and dermocosmetics industries. CTI-BIOTECH, a member of the<A title="" href="https://www.aderly.com/cosmetique-fashion-france/cosmetic-beauty-industry-dermocosmetology,p,63,EN.jsp" target=_blank>European Center of Dermocosmetology </A>for the past two years, <STRONG>will contribute its know-how to the industry by developing innovative in vitro cell models and by coordinating the biobank dedicated to the national personalized medicine program in the field of oncology</STRONG>.</P> <P align=justify><BR>The IMODI research project aims to facilitate the selection of new effective treatments for eight types of cancer. <STRONG>It will help to create 350 jobs at local partner companies over the next 10 years. </STRONG></P> <P><STRONG></STRONG>&nbsp;</P>